Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.


Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

Do you currently accept new Medicaid patients?

Do you currently accept new Medicaid patients?

The NHS has found that 31% of physicians were unwilling to accept new Medicaid patients.

How often do you try to persuade your patients who smoke to give up the habit?

How often do you try to persuade your ...

Doctors can play an important role in educating patients who smoke about the adverse health effects.

Is allowing patients direct access to lab results a good idea?

Is allowing patients direct access to lab results ...

A ruling from the HHS took effect allowing patients direct access to medical laboratory results.